ReviewLeukemia2021
Current challenges and unmet medical needs in myelodysplastic syndromes.
Review in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 97 citations in OpenAlex.
- US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.Blood advances · 2023Trial
- Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.Annals of hematology · 2023Trial
- Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.Annals of hematology · 2026Article
- Hematologic responses achieved with luspatercept in higher-risk myelodysplastic syndromes.Blood advances · 2026Article
- Proteomics in myelodysplastic syndromes: towards novel prognostic and diagnostic biomarkers.Biochemia medica · 2026Review
- Profiling Ten RHO GTPases in Myeloid Malignancies Reveals Distinct Expression Patterns and Prognostic Associations.Cancer medicine · 2026Article
- Quality and reliability of myelodysplastic syndromes-related health information on Chinese short-video platforms: a multi-platform cross-sectional analysis.Frontiers in digital health · 2026Article
- Decitabine-mediated DNA methylation dynamics at pericentromeric satellite 2 repeats.BMC cancer · 2025Article
- Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial.EClinicalMedicine · 2025Article
- Meeting Report From the 2024 Symposium on IRAK4 in Cancer: Highlights and Clinical Updates.Clinical lymphoma, myeloma & leukemia · 2025Review
- Factors associated with unmet medical needs among middle-aged and older adults in China during COVID-19 pandemic.BMC public health · 2025Article
- TP-0903 Suppresses Aurora A-PLK1 Signaling to Inhibit Proliferation of a Myelodysplastic Syndrome-Derived Cell Line.Cancer science · 2025Article
- Prognostic factors and overall survival for second primary malignancies in myelodysplastic syndromes: a Cox regression coupled with competing risk model based on Surveillance, Epidemiology, and End Results (SEER) database.Translational cancer research · 2025Article
- Prognostic value of post-transplantation measurable residual disease in patients with myelodysplastic syndrome: A prospective cohort study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.Cancers · 2025Article
- Outcomes in patients undergoing hematopoietic stem cell transplantation for myelodysplastic syndromes.Blood cell therapy · 2025Article
- Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes.Current hematologic malignancy reports · 2025Review
- Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches.Clinical hematology international · 2025Review
- Experiences with Higher-Risk Myelodysplastic Syndromes and Improving Patient-Centered Treatment Decision-Making: A Qualitative Study of Patients, Caregivers, and Providers.Cancer management and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of progression to acute myeloid leukemia. Most patients with MDS are affected by anemia and anemia-related symptoms, which negatively impact their quality of life. While many patients with MDS have lower-risk disease and are managed by existing treatments, there currently is no clear standard of care for many patients. For patients with higher-risk disease, the treatment priority is changing the natural history of the disease by delaying disease progression to acute myeloid leukemia and improving overall survival. However, existing treatments for MDS are generally not curative and many patients experience relapse or resistance to first-line treatment. Thus, there remains an unmet need for new, more effective but tolerable strategies to manage MDS. Recent advances in molecular diagnostics have improved our understanding of the pathogenesis of MDS, and it is becoming clear that the diverse nature of genetic abnormalities that drive MDS demands a complex and personalized treatment approach. This review will discuss some of the challenges related to the current MDS treatment landscape, as well as new approaches currently in development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.